Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases

References

• American Cancer Society. Breast Cancer Facts and Figures 2011-2012. Atlanta, GA: American Cancer Society, 2011
   Google Scholar
• Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006;56168-83.
   Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(8 Suppl):1588-94.
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-45.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
   PubMed Web of Science ®Google Scholar
• Brown JE, Cook RJ, Lipton A, et al. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 2010;123:767-79.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2. 2012. Fort Washington, PA: National Comprehensive Cancer Network, Inc., 2012.
   Google Scholar
• Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-21.
   PubMed Web of Science ®Google Scholar
• Gordon DH. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clin Breast Cancer 2005;6:125-31.
   PubMedGoogle Scholar
• Weinfurt KP, Castel LD, Li Y, et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004;42:164-75.
   PubMed Web of Science ®Google Scholar
• Costa L, Badia X, Chow E, et al. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008;16:879-89.
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;3:CD003474.
   Google Scholar
• Abernethy AP, Herndon 2nd, JE, Wheeler JL, et al. Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology. J Pain Symptom Manage 2009;37:1027-38.
   PubMed Web of Science ®Google Scholar
• Abernethy AP, Zafar SY, Uronis H, et al. Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. J Pain Symptom Manage 2010;40:545-58.
   PubMedGoogle Scholar
• Fortner B, Baldwin S, Schwartzberg L, et al. Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. J Pain Symptom Manage 2006;31:207-14.
   PubMedGoogle Scholar
• Houts AC, Lipinski D, Olsen JP, et al. Use of the Patient Care Monitor to screen for depression in adult cancer patients interviewed with the structured clinical interview for DSM-IV. Psychooncology 2010;19:399-407.
   PubMedGoogle Scholar
• Stepanski EJ, Walker MS, Schwartzberg LS, et al. The relation of trouble sleeping, depressed mood, pain and fatigue in patients with cancer. J Clin Sleep Med 2009;5:132-6.
   PubMed Web of Science ®Google Scholar
• Walker MS, Schwartzberg LS, Stepanski EJ, et al. A retrospective study of quality of life in a community sample of patients with early stage breast cancer. Breast Cancer Res Treat 2009;115:415-22.
   PubMedGoogle Scholar
• Littell RC, Pendergast J, Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat Med 2000;19:1793-19.
   PubMed Web of Science ®Google Scholar
• Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997;16:2349-80.
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24.
   Web of Science ®Google Scholar
• Dehejia RH, Wahba S. Causal effects in nonexperimental studies: reevaluating the evaluation of training programs. J Am Stat Assoc 1999;94:1053-62.
   Web of Science ®Google Scholar
• Copay AG, Subach BR, Glassman SD, et al. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007;7:541-6.
   PubMed Web of Science ®Google Scholar
• Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15.
   PubMedGoogle Scholar
• Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008;61:102-9.
   PubMed Web of Science ®Google Scholar
• Jensen AO, Jacobsen JB, Norgaard M, et al. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 2011;11:29.
   PubMed Web of Science ®Google Scholar
• Wong MH, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2012;2:CD003474.
   Google Scholar